Drugs / Cryoprecipitate Antihemophilic Factor
Cryoprecipitate Antihemophilic Factor
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07265843 Comparator | Jan 2026 → Mar 2028 expected | — | Trauma Hemostatis and Oxygenation Research (THOR) Network | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cryoprecipitate Antihemophilic Factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07265843 ↗ |
| Known as | AHF | “Cryoprecipitate Antihemophilic Factor (AHF), also known as cryo, is a frozen blood product prepared from blood plasma.” NCT07265843 ↗ |
| Known as | cryo | “Cryoprecipitate Antihemophilic Factor (AHF), also known as cryo, is a frozen blood product prepared from blood plasma.” NCT07265843 ↗ |
| Action | Restore | “It is used for fibrinogen supplementation, particularly for hypofibrinogenemia fibrinogen, anemia associated with bleeding or congenital deficiency.” NCT07265843 ↗ |
| Modality | Protein / enzyme biologic | “Cryoprecipitate Antihemophilic Factor (AHF), also known as cryo, is a frozen blood product prepared from blood plasma.” NCT07265843 ↗ |